A Phase 1b Randomized, Investigator/Participant-Blind, Placebo-Controlled, Multiple-Ascending Dose Trial to Evaluate the Safety, Tolerance and Pharmacokinetics of JS1-1-01 in Healthy Subjects
Latest Information Update: 22 Nov 2024
At a glance
- Drugs JS1-1-01 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Tasly Pharmaceutical Group
- 17 Nov 2024 Status changed from recruiting to completed.
- 26 Dec 2022 New trial record